Medically Guided Weight Management With Tirzepatide
Begin a structured medical weight management programme with tirzepatide (Mounjaro), supported by physician assessment, clinical monitoring, and an individualised treatment plan.
Treatment Overview
Tirzepatide is a prescription medication that acts on GIP and GLP-1 receptors and may be prescribed as part of a medically supervised weight management programme where clinically appropriate.
Your programme begins with a medical weight management consultation to assess your medical history, current medications, weight-related health factors, lifestyle, and treatment goals. Your prescribing clinician will determine whether tirzepatide is appropriate for you and establish the dosing regimen based on your individual clinical needs.
Choose the programme duration that best suits your planned treatment and follow-up schedule:
4 Weeks – Initial programme for clients beginning their medically supervised treatment journey.
6 Weeks – Extended support with additional time for clinical monitoring and treatment adjustment where appropriate.
8 Weeks – A longer programme designed to provide continued medical oversight and progress monitoring.
12 Weeks – Comprehensive support over a three-month period with continued monitoring and treatment management.
*Programme duration does not determine your medication dose. Dose selection and any adjustments are made by the prescribing clinician based on your individual response, tolerability, and clinical requirements.*
Key Benefits
✓ Physician-led weight management
✓ Individualised tirzepatide treatment planning
✓ Structured clinical monitoring
✓ Regular assessment of treatment response
✓ Support with sustainable weight management goals
✓ Ongoing guidance throughout your selected programme
Ideal For
• Adults seeking medically supervised weight management
• Individuals who may be clinically appropriate for tirzepatide treatment
• Clients who have struggled with weight management through lifestyle changes alone
• Individuals seeking structured medical support for weight reduction
• Clients who value ongoing clinical monitoring and accountability
What To Expect
Your programme begins with a comprehensive medical weight management consultation. Your health history, current medications, relevant medical conditions, weight-related factors, and treatment goals will be reviewed.
If tirzepatide is considered appropriate, your clinician will determine the starting dose and treatment schedule. Your response and tolerability will be monitored throughout the programme, with treatment adjustments made when clinically indicated.
Ongoing Monitoring
Weight management with prescription medication requires ongoing clinical oversight. Follow-up assessments may be used to monitor your progress, discuss side effects or concerns, assess treatment response, and determine whether your treatment plan should be continued or adjusted.
Important Safety Information
Tirzepatide is a prescription medication and is not appropriate for everyone. Your suitability must be determined by a qualified healthcare professional before treatment begins.
Mounjaro carries a boxed warning regarding the risk of thyroid C-cell tumours observed in animal studies and is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other important precautions include pancreatitis, gallbladder disease, gastrointestinal adverse effects, hypersensitivity reactions, and risks associated with dehydration.
Common adverse reactions include nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.
Consultation Required
A medical weight management consultation is required before tirzepatide can be prescribed. Treatment is only initiated when clinically appropriate following an assessment by the prescribing clinician.
